• Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE) Registry Uptravi® (Selexipag) Users Registry PROTOCOL: AC-065A402
• A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis. (20222253)
• An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease (20212063) OPEN ENROLLMENT
• A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (20210052) OPEN ENROLLMENT
• A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (Airleaf™)
• A 52-week study assessing exacerbation rate, asthma control and safety in adult severe eosinophilic asthmatics treated with depemokimab compared with mepolizumab or benralizumab
• myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD patients in the home – a multi-center randomized controlled trial OPEN ENROLLMENT
• Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Patients Hospitalized for Viral Lung Infection Requiring Supplemental Oxygen OPEN ENROLLMENT
• A Study of the Efficacy and Safety of Treatment With MNKD-101 When Added to GBT in Participants with Pulmonary Nontuberculous Mycobacterial Infection OPEN ENROLLMENT
• The American Lung Association (ALA) Lung Health Cohort (LHC) OPEN ENROLLMENT